NASDAQ · Biotechnology

iTeos Therapeutics, Inc. (ITOS) Stock

$10.15 +0.20% NASDAQ: ITOS Healthcare

iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients.

Valuation

MetricValue
Price$10.15
Market Cap$448.68M
P/E Ratio-3.89
P/B Ratio0.90
P/S Ratio12.82
EPS (TTM)$-3.32
52-Week High$17.63
52-Week Low$4.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-21.44%
ROA-18.19%
ROCE-22.40%
Gross Margin-457.14%
Operating Margin-457.14%
Net Margin-382.86%
Debt/Equity0.01
Current Ratio7.53

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$345.0M$268.0M$13.0M$35.0M
Operating Profit$-45.0M$245.0M$126.0M$-151.0M$-160.0M
Net Profit$-38.0M$215.0M$97.0M$-113.0M$-134.0M
EPS$-1.24$5.68$2.56$-3.15$-3.32
Op Margin—71.0%47.2%-1199.7%-455.8%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$345.0M$885.0M$755.0M$668.0M$687.0M
Total Liabilities$21.0M$332.0M$92.0M$92.0M$97.0M
Cash$336.0M$849.0M$285.0M$251.0M$142.0M
Borrowings$0$5.0M$5.0M$6.0M$5.0M

Latest News

Florida subpoenas General Mills over flour Just Food · Jul 16, 2026 New RGTM standard aims to improve fibre identification in textiles Just Style · Jul 16, 2026 Australia winegrape crush smallest since 2000 – government figures Just Drinks · Jul 16, 2026 Net Asset Value(s) Business Wire · Jul 16, 2026 Citizens Financial Group, Inc. Reports Second Quarter 2026 Net Income of $587 Million, up 35% YoY, and EPS of $1.30, up 41% YoY and 15% QoQ Business Wire · Jul 16, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-25.0M$513.0M$-111.0M$-104.0M$-98.0M
Investing Cash Flow$-1.0M$-2.0M$-447.0M$70.0M$-133.0M
Financing Cash Flow$2.0M$1.0M$1.0M$1.0M$2.0M
Net Cash Flow$316.0M$512.0M$-564.0M$-34.0M$-109.0M
Free Cash Flow$-26.0M$512.0M$-112.0M$-107.0M$-100.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.07
EV / EBITDA-2.46
FCF Yield-17.07%
Quick Ratio7.53
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCYPBig Cypress Acquisition Corp. $8.44 -19.23% 19.63 $425.36M 0.00%
CKPTCheckpoint Therapeutics, Inc. $4.26 +0.00% -3.00 $367.72M 0.00%
CLYM $14.00 +0.00% -11.77 $801.68M 0.00%
GTHXG1 Therapeutics, Inc. $7.16 +0.14% -7.70 $377.75M 0.00%
IVVD $0.55 +3.10% -3.53 $162.51M 0.00%

About iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.

iTeos Therapeutics, Inc. is headquartered in US.

iTeos Therapeutics, Inc. (ITOS) stock trades at $10.15 with a market capitalization of $448.68M. The stock is valued at a price-to-earnings (P/E) ratio of -3.89, price-to-book of 0.90, price-to-sales of 12.82. Over the past 52 weeks the stock has ranged between $4.80 and $17.63, and currently trades 42.4% below its 52-week high.

On profitability, iTeos Therapeutics, Inc. generates a return on equity (ROE) of -21.44%, return on capital employed of -22.40%, an operating margin of -457.14%, a net profit margin of -382.86%.

Official website: www.iteostherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides